Health Care [ 5/12 ] | Biotechnology [ 33/74 ]
NASDAQ | Common Stock
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity.
Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 26 | 0.05 Increased by +126.32% | -0.50 Increased by +109.92% |
| Mar 18, 26 | -0.69 Decreased by -134.85% | -0.34 Decreased by -102.76% |
| Nov 6, 25 | -0.62 Decreased by -14.81% | -0.63 Increased by +1.59% |
| Aug 6, 25 | -0.55 Decreased by -10.00% | -0.58 Increased by +5.17% |
| May 5, 25 | -0.19 Decreased by -105.83% | 0.11 Decreased by -272.73% |
| Feb 25, 25 | 1.98 Increased by +350.00% | 0.25 Increased by +692.00% |
| Nov 4, 24 | -0.54 Increased by +6.90% | -0.60 Increased by +10.00% |
| Aug 6, 24 | -0.50 Increased by +26.47% | -0.60 Increased by +16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 56.37 M Increased by +99.03% | 3.78 M Increased by +132.46% | Increased by +6.71% Increased by +116.31% |
| Dec 31, 25 | 7.44 M Decreased by -95.64% | -44.38 M Decreased by -133.71% | Decreased by -596.80% Decreased by -873.40% |
| Sep 30, 25 | 4.71 M Increased by +0.79% | -39.34 M Decreased by -18.46% | Decreased by -834.87% Decreased by -17.53% |
| Jun 30, 25 | 5.55 M Increased by +33.09% | -34.77 M Decreased by -13.57% | Decreased by -626.96% Increased by +14.67% |
| Mar 31, 25 | 28.32 M Decreased by -88.89% | -11.65 M Decreased by -105.62% | Decreased by -41.15% Decreased by -150.60% |
| Dec 31, 24 | 170.64 M Increased by +184.40% | 131.67 M Increased by +381.70% | Increased by +77.17% Increased by +69.38% |
| Sep 30, 24 | 4.67 M Increased by +N/A% | -33.21 M Increased by +2.62% | Decreased by -710.37% Decreased by N/A% |
| Jun 30, 24 | 4.17 M Increased by +N/A% | -30.62 M Increased by +20.40% | Decreased by -734.73% Decreased by N/A% |